Jieqiong Peng Qiang Zhu Ziru Peng Zhen Chen Yuantao Liu Bo Liu
10.3389/fimmu.2022.1049518
Front Immunol
2022 Dec 8;13:1049518.
ak104/cadonilimab her-2 positive pd-1/ctla-4 bispecific advanced gastroesophageal junction cancer complete response
CC BY
https://pubmed.ncbi.nlm.nih.gov/36569905/
Esophageal Neoplasms / drug therapy Esophageal Neoplasms / pathology Hepatitis / pathology Stomach Neoplasms / drug therapy Stomach Neoplasms / genetics Stomach Neoplasms / metabolism
Esophageal Neoplasms / drug therapy Esophageal Neoplasms / pathology Hepatitis / pathology Stomach Neoplasms / drug therapy Stomach Neoplasms / genetics Stomach Neoplasms / metabolism Case Reports Research Support, Non-U.S. Gov't Adult CTLA-4 Antigen Esophagogastric Junction / pathology Humans Male Positron Emission Tomography Computed Tomography Programmed Cell Death 1 Receptor Programmed Cell Death 1 Receptor CTLA-4 Antigen
PMC9773983
36569905
Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104/cadonilimab (PD-1/CTLA-4 bispecific): A case report
2022